Press Releases

Dec 10, 2024
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical
Oct 09, 2024

We're excited to announce that Lisata's President and CEO, Dr. David J. Mazzo, has been named one of PharmaVoice's 100 most inspiring leaders in the life sciences space! This prestigious list honors the industry's most impactful executives, and Dr. Mazzo's recognition is a testament to his

Displaying 1 - 10 of 35